Molybdenum – and tungsten(II) monometallic 3-(2-pyridyl)pyrazole and bimetallic 3-(2-pyridyl)pyrazolate complexes

Molybdenum and tungsten complexes containing the pypzH (3-(2-pyridyl)pyrazole) ligand as a chelating bidentate are prepared: [Mo(CO)(4)(pypzH)], cis-[MoBr(eta(3)-allyl)(CO)(2)(pypzH)], cis-[MoCl(eta(3)-methallyl)(CO)(2)(pypzH)], [MI2(CO)(3)(pypzH)] (M = Mo, W) from [Mo(CO)(4)(NBD)] or the adequate bis(acetonitrile) complexes. The deprotonation of the molybdenum allyl or methallyl complexes affords the bimetallic complexes [cis-{Mo(eta(3)-allyl)(CO)(2)(mu(2)-pypz)}](2) or [cis-{Mo(eta(3)-methallyl)(CO)(2)(mu(2)-pypz)}](2) (mu(2)-pypz = mu(2)-3-(2-pyridyl-kappa N-1) pyrazolate-2 kappa N-1). The allyl complex was subjected to an electrochemical study, which shows a marked connection between both metallic centres through the bridging pyridylpyrazolates.

O ensino da música no 2º e 3º ciclo do ensino básico

Relatório apresentado para cumprimento dos requisitos necessários à obtenção do grau de Mestre em Ensino de Educação Musical no Ensino Básico.

Effect of sulfate and iron (III) on LCFA degradation by a methanogenic community

[Excerpt] Under anaerobic conditions long chain fatty acids (LCFA) can be converted to methane by syntrophic bacteria and methanogenic archaea. LCFA degradation was also reported in the presence of alternative hydrogenotrophic partners, such as sulfate-reducing bacteria (SRB) and iron-reducing bacteria (IRB), which generally show higher affinity for H2 than methanogens and are more resistant to LCFA [1,2,3]. Their presence in a microbial culture degrading LCFA can be advantageous to reduce LCFA toxicity towards methanogens, although high concentrations of external electron acceptor (EEA) can lead to outcompetition of methanogens and cease methane production. In this work, we tested the effect of adding sub-stoichiometric concentrations of sulfate and iron(III) to methanogenic communities degrading LCFA. (...)

პოეტ-აკადემიკოს ი. გრიშაშვილის ბიბლიოთეკა-მუზეუმის კატალოგი. ტ.3, ნაწ.2

კატალოგში აღწერილი და მეცნიერულად დამუშავებულია აკადემიკოს ი. გრიშაშვილის ბიბლიოთეკა-მუზეუმში დაცული რუსულ ენაზე დაბეჭდილი წიგნები. ბევრი მათგანი ბიბლიოგრაფიულ იშვიათობას წარმოადგენს. არის უნიკალური გამოცემები XVIII-XIX ს.ს. კლასიკოსებისა და მწერლების წიგნები ავტოგრაფებით. XX ს. 20-იანი წლების თბილისის გამოცემები. მნიშვნელოვანია წიგნებზე ი. გრიშაშვილის მარგინალიები, რომლებიც მრავალ საინტერესო ცნობებს შეიცავს.

Absorção de nutrientes por duas cuitivares de girassol (Helianthus annuus L.), em condições de campo: III. Acúmulo de macronutrientes

Para se estudar o acúmulo de macronutrientes em função da idade das plantas de girassol, instalou-se um experimento, em condições de campo, no Centro Nacional de Pesquisa de Soja, em Londri na (PR). O solo utilizado foi Latossolo Roxo eutrófico e o delineamento estatístico foi o inteiramente casua1izado com quatro repetições. Foram aplicadas seis doses de adubação N, P e K, das quais se escolheram as doses 0-0-0 e 90-45-45 kg/ha para a cultivar 'Contissol' e 0-0-0 e 45-45-45 kg/ha para a cultivar 'Guayacan'. A coleta de amostras foi de 14 em 14 dias a partir da emergencia das plantas. Pode-se conc1uir: - o acúmulo máximo de nutrientes ocorreu próximo aos 87 dias e o ponto de inflexão aos 55 dias após a emergência; - as quantidades totais de macronutrientes, absorvidas pelas plantas , obedecem à seguinte ordem: K>N>Ca>Mg>P>S; - a exportação de macronutrientes através da colheita de grãos segue a ordem: N > K > P > Mg > Ca > S; - o acúmulo máximo em kg de macronutrientes para uma produção de 1.000 kg de grãos foi : k=141; n =94; Ca = 68; Mg = 23 ; P = 14; S = 5. - A exportação em kg de macronutrientes para produção de 1.000 kg de grãos foi : N = 31,5; K = 9,5; P = 5,3; Mg = 3,0; Ca = 2,3 e S = 1,0.

Non compact euclidean cone 3-manifolds with cone angles less than 2∏

We study of noncompact Euclidean cone manifolds with cone angles less than c&2π and singular locus a submanifold. More precisely, we describe its structure outside a compact set. As a corol lary we classify those with cone angles & 2π/3 and those with cone angles = 2π/3.

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.

PURPOSE: The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. METHODS: Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for FISH testing. Testing was performed in 16 participating centers, using the same protocol after passing external quality assessment. RESULTS: Positive ALK IHC staining was present in 80 patients (prevalence of 6.2%; 95% CI, 4.9% to 7.6%). Of these, 28 patients were ALK FISH positive, corresponding to a lower bound for the prevalence of FISH positivity of 2.2%. FISH specificity was 100%, and FISH sensitivity was 35.0% (95% CI, 24.7% to 46.5%), with a sensitivity value of 81.3% (95% CI, 63.6% to 92.8%) for IHC 2+/3+ patients. The hazard of death for FISH-positive patients was lower than for IHC-negative patients (P = .022). Multivariable models, adjusted for patient, tumor, and treatment characteristics, and matched cohort analysis confirmed that ALK FISH positivity is a predictor for better overall survival (OS). CONCLUSION: In this large cohort of surgically resected lung adenocarcinomas, the prevalence of ALK positivity was 6.2% using IHC and at least 2.2% using FISH. A screening strategy based on IHC or H-score could be envisaged. ALK positivity (by either IHC or FISH) was related to better OS.

Indicateurs de résultats du Promedro III, situation en 2008 : rapport final

[Table des matières] 1. Introduction. 1.1. Rappel du mandat. 1.2. Méthode. 2. Résultats. 2.1. Indicateurs du nombre de consommateurs. 2.2. Indicateurs des problèmes en relation (ou non) avec les drogues chez les jeunes. 2.3. Indicateurs en relation avec la consommation problématique de drogues dures en général. 2.4. Indicateurs des conséquences négatives pour les usagers de drogues illégales. 2.5. Indicateurs des conséquences négatives pour la société. 3. Annexe.

Updated survival data of the phase iii clinical trial of novottf-100a versus best standard chemotherapy for recurrent glioblastoma

NovoTTF-100A (TTF) is a portable device delivering low-intensity, intermediate-frequency, alternating electric fields using noninvasive, disposable scalp electrodes. TTF interferes with tumor cell division, and it has been approved by the US Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma (rGBM) based on data from a phase III trial. This presentation describes the updated survival data 2 years after completing recruitment. Adults with rGBM (KPS ≥ 70) were randomized (stratified by surgery and center) to either continuous TTF (20-24 h/day, 7 days/week) or efficacious chemotherapy based on best physician choice (BPC). The primary endpoint was overall survival (OS), and secondary endpoints were PFS6, 1-year survival, and QOL. Patients were randomized (28 US and European centers) to either TTF alone (n ¼ 120) or BPC (n ¼ 117). Patient characteristics were balanced, median age was 54 years (range, 23-80 years), and median KPS was 80 (range, 50-100). One quarter of the patients had debulking surgery, and over half of the patients were at their second or later recurrence. OS in the intent-to-treat (ITT) population was equivalent in TTF versus BPC patients (median OS, 6.6vs. 6.0 months; n ¼ 237; p ¼ 0.26; HR ¼ 0.86). With a median follow-up of 33.6 months, long-term survival in the TTF group was higher than that in the BPC group at 2, 3, and 4 years of follow-up (9.3% vs. 6.6%; 8.4% vs. 1.4%; 8.4% vs. 0.0%, respectively). Analysis of patients who received at least one treatment course demonstrated a survival benefit for TTF patients compared to BPC patients (median OS, 7.8 vs. 6.0 months; n ¼ 93 vs. n ¼ 117; p ¼ 0.012; HR ¼ 0.69). In this group, 1-year survival was 28% vs. 20%, and PFS6 was 26.2% vs. 15.2% (p ¼ 0.034). TTF, a noninvasive, novel cancer treatment modality shows significant therapeutic efficacy with promising long-term survival results. The impact of TTF was more pronounced when comparing only patients who received the minimal treatment course. A large-scale phase III trial in newly diagnosed GBM is ongoing.